Clare Bailey1, Lauren J Scott2, Chris A Rogers2, Barnaby C Reeves2, Barbra Hamill3, Tunde Peto4, Usha Chakravarthy5, Simon P Harding6. 1. Bristol Eye Hospital, Bristol, United Kingdom. 2. Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol Royal Infirmary, Bristol, United Kingdom. 3. Belfast Reading Centre, Queens University Belfast, Royal Victoria Hospital, Belfast, United Kingdom. 4. Department of Ophthalmology, Queens University Belfast, Belfast, United Kingdom. 5. Department of Ophthalmology, Queens University Belfast, Belfast, United Kingdom; Centre for Public Health, Queen's University of Belfast, Belfast, United Kingdom. 6. Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom. Electronic address: s.p.harding@liv.ac.uk.
Abstract
PURPOSE: To report on the development and progression of macular atrophy (MA) and its relationship with morphologic and functional measures in study and fellow eyes in the Inhibition of vascular endothelial growth factor (VEGF) in Age-related Choroidal Neovascularisation trial. DESIGN: Reading center analysis of data from a randomized controlled trial. PARTICIPANTS: Participants with previously untreated neovascular age-related macular degeneration (nAMD) in the study eye. METHODS:Color, fluorescein angiography (FA) and OCT images acquired at baseline and during the 2-year follow-up were graded systematically for presence of MA. Regression models were constructed to explore relationships between MA and lesion morphology and vision measures (best-corrected distance and near acuity, reading speed and index, contrast sensitivity). MAIN OUTCOME MEASURES: Primary outcome was development of intralesional MA (≥175 μm greatest linear dimension of choroidal vessels seen on FA and/or color, aided by OCT) lying within the maximum footprint of the neovascular lesion. RESULTS: Study eye data were available for 594 of 610 participants; 57 (9.6%) showed intralesional MA at baseline. Incident intralesional MA occurred in 24.4% by the final visit and extralesional MA in only 1.54%. In fellow eyes, an established nAMD lesion was present at baseline in 248 of whom 42 (16.9%) showed intralesional MA at baseline and 32 (12.9%) developed incident intralesional MA. The odds of incident intralesional MA by final visit were lower in study eyes that had ≥50% classic CNV at baseline (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.19-0.80; P = 0.010), subretinal fluid at final visit (OR, 0.41; 95% CI, 0.25-0.76; P = 0.004), or pigment epithelial detachment at final visit (OR, 0.40; 95% CI, 0.21-0.74; P = 0.004). Secondary analyses of incident or progressed intralesional MA in study eyes supported these findings, with odds increasing if the fellow eye had baseline intralesional MA (OR, 2.43; 95% CI, 1.09-5.44; P = 0.030). No significant associations were observed between development of intralesional MA and any other morphologic or visual function measure. CONCLUSIONS: Macular atrophy frequently develops within an nAMD lesion in eyes receiving anti-VEGF therapy over 2 years. No associations between incident MA and drug or treatment frequency or visual function were detected, providing some reassurance to clinicians; however, the longer-term effects remain unknown.
RCT Entities:
PURPOSE: To report on the development and progression of macular atrophy (MA) and its relationship with morphologic and functional measures in study and fellow eyes in the Inhibition of vascular endothelial growth factor (VEGF) in Age-related Choroidal Neovascularisation trial. DESIGN: Reading center analysis of data from a randomized controlled trial. PARTICIPANTS: Participants with previously untreated neovascular age-related macular degeneration (nAMD) in the study eye. METHODS: Color, fluorescein angiography (FA) and OCT images acquired at baseline and during the 2-year follow-up were graded systematically for presence of MA. Regression models were constructed to explore relationships between MA and lesion morphology and vision measures (best-corrected distance and near acuity, reading speed and index, contrast sensitivity). MAIN OUTCOME MEASURES: Primary outcome was development of intralesional MA (≥175 μm greatest linear dimension of choroidal vessels seen on FA and/or color, aided by OCT) lying within the maximum footprint of the neovascular lesion. RESULTS: Study eye data were available for 594 of 610 participants; 57 (9.6%) showed intralesional MA at baseline. Incident intralesional MA occurred in 24.4% by the final visit and extralesional MA in only 1.54%. In fellow eyes, an established nAMD lesion was present at baseline in 248 of whom 42 (16.9%) showed intralesional MA at baseline and 32 (12.9%) developed incident intralesional MA. The odds of incident intralesional MA by final visit were lower in study eyes that had ≥50% classic CNV at baseline (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.19-0.80; P = 0.010), subretinal fluid at final visit (OR, 0.41; 95% CI, 0.25-0.76; P = 0.004), or pigment epithelial detachment at final visit (OR, 0.40; 95% CI, 0.21-0.74; P = 0.004). Secondary analyses of incident or progressed intralesional MA in study eyes supported these findings, with odds increasing if the fellow eye had baseline intralesional MA (OR, 2.43; 95% CI, 1.09-5.44; P = 0.030). No significant associations were observed between development of intralesional MA and any other morphologic or visual function measure. CONCLUSIONS:Macular atrophy frequently develops within an nAMD lesion in eyes receiving anti-VEGF therapy over 2 years. No associations between incident MA and drug or treatment frequency or visual function were detected, providing some reassurance to clinicians; however, the longer-term effects remain unknown.
Authors: Ebenezer Daniel; Maureen G Maguire; Juan E Grunwald; Cynthia A Toth; Glenn J Jaffe; Daniel F Martin; Gui-Shuang Ying Journal: JAMA Ophthalmol Date: 2020-05-01 Impact factor: 7.389
Authors: Panos G Christakis; Elvira Agrón; Michael L Klein; Traci E Clemons; J Peter Campbell; Frederick L Ferris; Emily Y Chew; Tiarnan D Keenan Journal: Ophthalmology Date: 2019-11-26 Impact factor: 12.079
Authors: Roy Schwartz; Alasdair Warwick; Abraham Olvera-Barrios; Maria Pikoula; Aaron Y Lee; Spiros Denaxas; Paul Taylor; Catherine Egan; Usha Chakravarthy; Peck Lin Lip; Adnan Tufail Journal: Ophthalmol Retina Date: 2021-04-16
Authors: Avni P Finn; Maxwell Pistilli; Vincent Tai; Ebenezer Daniel; Gui-Shuang Ying; Maureen G Maguire; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Cynthia A Toth Journal: Am J Ophthalmol Date: 2020-11-19 Impact factor: 5.258
Authors: Rebecca N Evans; Barnaby C Reeves; Maureen G Maguire; Daniel F Martin; Alyson Muldrew; Tunde Peto; Chris Rogers; Usha Chakravarthy Journal: JAMA Ophthalmol Date: 2020-10-01 Impact factor: 7.389